biostudies-literatureCampanilho-Marques RGreat Ormond Street Hospital CharityCure JMAction Medical ResearchVersus ArthritisMedical Research CouncilThe Henry Smith CharityNational Institute for Health Research (NIHR)Wellcome TrustThe Myositis Support GroupThe Myositis Association79https://www.ebi.ac.uk/biostudies/studies/S-EPMC7161150biostudies-literatureUnknown22(1)<h4>Background</h4>Anti-TNF treatment may be useful for the treatment of patients with refractory juvenile dermatomyositis (JDM). The aim of this study was to describe the use of infliximab and adalimumab therapy in juvenile dermatomyositis as an adjunctive treatment.<h4>Methods</h4>Sixty children recruited to the UK JDM Cohort and Biomarker Study that had received at least 3 months of anti-TNF treatment (infliximab or adalimumab) were studied. Childhood Myositis Assessment Scale (CMAS), Manual Muscle Testing (MMT8) and physician's global assessment (PGA) were recorded. Skin disease was assessed using the modified skin disease activity score (DAS). Data were analysed using Friedman's test for repeated measures analysis of variance.<h4>Results</h4>Compared to baseline, there were improvemenArthritis research & therapyRetrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients.PMC7161150MR/N003322/1n/a1451808586021552NF-SI-0616-1009920164SP4252V1268McCann LCollier APluess-Hall HRyder CSatyapal RJuvenile Dermatomyositis Research Group (JDRG)Frost AJohnson-Moore CO'Brien KBoros CVarnier GEllis-Gage JMosley EMartin NConnon MEnayat ECiurtin CHall JMaillard SKendall EStafford SBriggs VLloyd OFriswell MSandhu KBailey KHanson SQiao LThomas BMcMahon AMStevenson VRoper HLee HWaxman LStretton EHasson NAndrews MDeakin CRiley PWedderburn LTurner LCrate LAl-Obadi MNistala KMiller DMacleod EBooth TWadeson SDuong CAl-Abadi EHaslam KFerguson SHalkon EVenning HBaildam EVanRooyen VDeakin CTBass-Woodcock CLeach SAmin TSuffield LVallance LBeard LRoberts IWood MAkeroyd LKingshott RFofana ESketchley SWatson SClifford CWarrier KDandy TCutts RWyatt SChisem HMurray KHanna LSen EMarques REtherton RVarsani HWilkinson MMutten MFoster HWilkinson NPratt DCaruana LGardner-Medwin JIoannou JAlmeida BWade DDavidson BArmon KBoyle RGlackin YHowman RSouthwood TDavidson JMcGovern ABrowne MArnold KClinch JHartfree SDowle SDe Graaf HCuthbert VScott JKhaosut PLacassagne SJordan MMayers DSimou SStone LWedderburn LRJackson GInness EBurton DLeahy AMarshall LPilkington CPilkington CASmith HFineman NSmith ECampanilho-Marques RWatts JBlyth EJuggins ASmith SYasin SLunt SKassoumeri LPapadopoulou CSwift AJandial SBrown VRobinson EPiper CfalseRetrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients.<h4>Background</h4>Anti-TNF treatment may be useful for the treatment of patients with refractory juvenile dermatomyositis (JDM). The aim of this study was to describe the use of infliximab and adalimumab therapy in juvenile dermatomyositis as an adjunctive treatment.<h4>Methods</h4>Sixty children recruited to the UK JDM Cohort and Biomarker Study that had received at least 3 months of anti-TNF treatment (infliximab or adalimumab) were studied. Childhood Myositis Assessment Scale (CMAS), Manual Muscle Testing (MMT8) and physician's global assessment (PGA) were recorded. Skin disease was assessed using the modified skin disease activity score (DAS). Data were analysed using Friedman's test for repeated measures analysis of variance.<h4>Results</h4>Compared to baseline, there were improvemen2020-01-01T00:00:00Z2020 Apr2025-04-04T10:24:09.714Z2020-05-22T17:55:32ZS-EPMC71611503229353910.1186/s13075-020-02164-5